NCT06058377

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2023-11-27Est. Completion: 2032-05-31

Enrollment target: 3,680 participants

Locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Katmai Oncology Group, Anchorage, Alaska, United States
University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
Banner University Medical Center - Tucson, Tucson, Arizona, United States
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Sutter Auburn Faith Hospital, Auburn, California, United States
AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California, United States
Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
Tower Cancer Research Foundation, Beverly Hills, California, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Palo Alto Medical Foundation-Fremont, Fremont, California, United States

Other microbiome trials you might be interested in

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPhase 3Recruiting

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone thera…

Bloomington, United StatesEst. completion Jul 31, 2029

View Trial →

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialPhase 3Recruiting

Anatomic Stage II Breast Cancer AJCC v8

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.